Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
نویسندگان
چکیده
منابع مشابه
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhibitors (TKIs), which might be more potent than crizotinib or effective on crizotinib-resistant pat...
متن کاملAn ALK-positive NSCLC patient with the G1202R mutation detected by next-generation sequencing
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors are currently essential drugs in the treatment of the subset of patients with non-small-cell lung cancer (NSCLC) showing ALK rearrangement. Notwithstanding, even the response to ALK inhibitors is usually not sustained in these patients, because of the occurrence of secondary mutations in ALK, MET amplification, or other unknown alterat...
متن کاملTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
PURPOSE The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC). Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients. As patients still relapse even on these next-generation ALK-TKIs, we examined mechanisms of resistance to...
متن کاملALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
PURPOSE EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance limits their ultimate efficacy. Thus, a better understanding of resistance mechanisms will help to enhance tumor control in EML4-ALK-positive tumors. EXPERIMENTAL DESIGN By ap...
متن کاملALK and NSCLC: Targeted therapy with ALK inhibitors
For many years treatment for advanced or metastatic non-small cell lung cancer (NSCLC) has employed chemotherapy regimens for patient care, with limited effect. Five-year survival rates for these patients are not encouraging. However, for a subgroup of these patients, there have been radical changes over recent years. Our understanding of the basic pathology behind NSCLC at the molecular level ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Lung Cancer Research
سال: 2020
ISSN: 2218-6751,2226-4477
DOI: 10.21037/tlcr.2020.02.07